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ABSTRACT
Background: Recent progress in the diagnosis and treatment of primary and 
metastatic cutaneous melanoma (CM) has led to a significant increase in the patients` 
expectancy of life. The development of additional primary tumors (APT) other than 
CM represents an important survival issue. 
Results: Of a total of 1764 CM patients, 80 (4.5%) patients developed APT. For 
tumors diagnosed after CM, there was a 2.7 fold excess risk for APT compared to the 
swiss german population. A significantly increased risk was noted for female breast 
(SIR, 2.46), male larynx (SIR, 76.92), male multiple myeloma (SIR, 11.2), male 
oesophagus (SIR, 10.8) and thyroid on males (SIR, 58.8) and females (SIR, 38.1). All 
thyroid cancer cases had a common papillary histological subtype and a high rate of 
BRAFV600E mutation. Melanoma was the primary cause of death in the vast majority 
of patients. 
Methods: We used the cancer registry from the Comprehensive Cancer Center 
Zurich (CCCZ) and retrospectively analyzed patients with CM and APT between 2008 
and 2018. We calculated the risk of APT compared to the swiss german population 
using the standardized incidence ratio (SIR). 
Conclusions: Patients with CM have an increased risk for hematologic and solid 
APT. Long-term follow-up is indicated. 
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INTRODUCTION
Cancer is a genetic disease, caused by the 
accumulation of genetic mutations that eventually transform 
a normal cell into a tumor cell [1]. It is of great concern 
for industrial countries due to the increasing incidence rates 
of the most common forms of cancer, mostly due to the 
lengthening of human lifespan and population aging [2, 3]. 
Cutaneous melanoma (CM) is, when not diagnosed early, 
an aggressive skin cancer derived from the melanocytes [4]. 
Although it represents approximately 5% of all cutaneous 
malignancies, it is considered one of the most lethal form 
of all skin cancers. Recent advances in understanding the 
molecular mechanisms and the underlying pathogenesis 
of the disease has led to significant improvements in 
the diagnosis and treatment and subsequently to an 
increase of the melanoma survival rates [5]. Due to 
variable environmental factors resulting in DNA damage, 
melanoma is associated with a high burden of somatic 
mutations [6, 7]. The identification of frequent mutations 
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in the MAPK pathway has led to the development of 
targeted inhibitors, such as BRAF inhibitors (BRAFi) and 
MEK inhibitors (MEKi), with improved response and 
overall survival (OS) [8]. On the other hand, melanoma 
is an immunogenic cancer, conferring sensitivity to 
immunotherapeutic antibodies, which augment the cell-
mediated immunity, such as checkpoint inhibitors against 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or 
programmed cell-death protein 1 (PD-1) [9]. Due to this 
remarkable progress in metastatic melanoma treatment, 
today, the proportion of patients alive at 24 months in first-
line setting is 62.9% with anti-PD1 plus anti-CTLA4 and 
53.5% with BRAFi and MEKi [10].
Considering the tremendous improvement in the 
OS, it is also important to focus on survival issues and 
consequences, such as the development of long-term 
toxicities and most importantly new, independent tumors 
of different primaries other than melanoma. SEER-
database analyses have previously shown that melanoma 
patients are prone to the development of other primary 
tumors of different histological type [11] and vice versa; 
other malignancies have been related to a secondary 
melanoma development [12–17]. Since the diagnosis 
and treatment complexity of the patients with additional 
primary tumors (APT) increases, we retrospectively 
analyzed melanoma patients with primary tumors of 
histological type other than melanoma in our melanoma-
reference center. We aimed to describe the distribution of 
these tumors analog to melanoma diagnosis, underline the 
complexity of these patients and emphasize the importance 
of long-term follow-up in patients diagnosed with cancer. 
RESULTS
Study population
There was a total of one thousand seven hundred 
and sixty four (n = 1764) patients diagnosed with 
melanoma between 2008 and 2018 with a cut-off of June 
2018. Of the 1764 melanoma patients, eighty (4.5%) 
patients were diagnosed with an APT, from which 
thirteen (16.25%) patients developed multiple (> three) 
separate cancer types of different primary (MPT) (Figure 
1). The median patient age at melanoma diagnosis was 
70 years (33-90 years) and the majority of the patients 
were males (65%). Thirty (37.5%) patients had a family 
history of cancer, with same cancer in first- or second-
degree relatives in 8.8%. 60% of the patients diagnosed 
with an APT had metastatic melanoma of which 26.7% 
were metastatic to the brain. Since mutational analysis 
does not belong to the standard tests for patients with 
non-metastatic melanoma in our institution and 32.4% 
of the patients were stage III-IV, mutational status was 
known in 57% of the patients. 26.6% of these patients 
were BRAF V600 mutated and 16.5% NRAS. As of June 
2018 69.6% of the patients with APT were alive. Of the 
30.4% deceased, metastatic melanoma was the primary 
cause of death in the vast majority of patients (79.2%), 
followed by breast cancer (8.3%). Other causes of 
death were multiple myeloma (4.2%), pancreas cancer 
(4.2%) and lung cancer (4.2%). Patients’ characteristics, 
demographics and features of melanoma are listed in 
Table 1.
Figure 1: Patient population, CCCZ: Comprehensive Cancer Center Zurich.
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Table 1: Basic demographic characteristics of study population
  Overall
N  80
Age at first diagnosis (median (range))  70 (33–80)
Age group (%) 18,34 1 (1.2)
 35,49 7 (8.8)
 50,69 38 (47.5)
 70,90 34 (42.5)
Family history (%) First degree relative same cancer type 4 (5.0)
 First degree relative different cancer type 21 (26.2)
 Second degree relative same cancer type 3 (3.8)
 Second degree relative different cancer type 2 (2.5)
 No family history of cancer 36 (45.0)
 Unknown 14 (17.5)
Smoking (%) No 57 (71.2)
 1–9py 4 (5.0)
 10–19py 4 (5.0)
 20–29py 5 (6.2)
 30py+ 7 (8.8)
 Unknown 3 (3.8)
Race (%) Asian 1 (1.2)
 White 79 (98.8)
Sex (%) Female 28 (35.0)
 Male 52 (65.0)
Localisation of CM (%) Head and neck 17 (21.2)
 Trunk 27 (33.8)
 Upper extremities 9 (11.2)
 Lower extremities 13 (16.2)
 Acral 6 (7.5)
 Mucosal and uveal 3 (3.8)
 unknown 5 (6.2)
Type of CM(%) SSM 17 (21.2)
 NM 25 (31.2)
 LMM 6 (7.5)
 ALM 5 (6.2)
 Unknown primary 6 (7.5)
 Mucosal or Uveal 1 (1.2)
 Unclassified 15 (18.8)
 Unknown 5 (6.2)
Breslow (%) 0–1 mm 10 (12.7)
 1.01–2 mm 29 (36.7)
 2.01–4 mm 6 (7.6)
 >4 mm 23 (29.1)
 Unknown 11 (13.9)
Ulceration (%) No 35 (44.3)
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Additional primary tumors (APT)
In all, we found 93 second primary cancers, 
accounting also for multiple cancers, diagnosed before 
and after the first melanoma diagnosis between January 
2008 and June 2018. The most frequently observed APT 
was prostate cancer in males (24.7%) followed by breast 
cancer in females (15.1%). Other frequently observed 
cancers on the overall distribution were bladder cancer 
(7.5%), lung cancer (6.5%), thyroid cancer (6.5%), non-
hodgkin lymphoma (5.4%) and leukemia (5.4%) (Table 
2). No predominant leukemia type was found. There 
was diversity in the stage of first diagnosis of the APT 
with 31.2% in stage I, IA and IB and 16.2% in stage IV 
and IVA. Consequently, 44.1% of these APT received 
curative surgical resection only, 27.9% received curative 
resection combined either with radiotherapy (11.8%) or 
with systemic therapy (11.8%) or both (4.3%). Altogether, 
30.2% of the patients in our cohort required a systemic 
therapy; 10.8% alone, 11.8% combined with operation, 
1.1% with radiotherapy, 4.3% with both operation and 
radiotherapy and 2.12% with radiotherapy and bone 
marrow- or stem cell- transplantation. 6.5% of the APT 
were under follow up only. For information on the course 
of treatment see Table 2. 
Comparison of APT diagnosed before and after 
melanoma
We compared the APT diagnosed before (50.5%) 
and after (49.5%) the first melanoma diagnosis and 
analyzed for differences in site of occurrence according 
to sex (Figure 2). Breast cancer in females and prostate 
cancer in males remain the most frequently observed 
APT before and after the melanoma diagnosis, with a 
frequency of 12.8% and 17.4% respectively for breast 
cancer and 36.2% and 13% for prostate cancer (Table 
2). Bladder cancer in males occurs with a frequency of 
8.5% before CM and 4.3% after CM. In females, the 
second most frequent APT is leukemia (8.5%) before 
CM with no cases after CM and thyroid cancer (8.6%) 
after CM with no cases before CM. In our patient cohort, 
all thyroid cancer cases were observed after the first 
melanoma diagnosis in both sexes. On the contrary, the 
vast majority of hematologic malignancies (leukemia 
in females and non-hodgkin lymphoma in males) seem 
to occur before the melanoma diagnosis. Median time 
to APT diagnosis after CM was 15.91 months (range 
0–241.16) and median time to CM after APT diagnosis 
was 55.37 months (0.30–443.17) (Figure 3). On APT 
diagnosed before CM, 23.4% were stage I and 12.7% 
 Yes 22 (27.8)
 Unknown 22 (27.8)
Mutation Status (%) BRAF 21 (26.6)
 NRAS 13 (16.5)
 BRAF wild-type 3 (3.8)
 BRAF and NRAS wild-type 5 (6.3)
 cKIT 2 (2.5)
 MTOR 1 (1.3)
 Unknown 34 (43.0)
AJCC Stage at first diagnosis (%) Stage I or II 54 (67.5)
 Stage III 21 (26.2)
 Stage IV 5 (6.2)
Metastatic Melanoma (%) No 32 (40.0)
 Yes 48 (60.0)
CNS Metastasis (%) No 33 (73.3)
 Yes 12 (26.7)
Status (%) Alive 55 (69.6)
 Deceased 24 (30.4)
Death due to (%) Breast 2 (8.3)
 Lung 1 (4.2)
 Melanoma 19 (79.2)
 Multiple Myeloma 1 (4.2)
 Pancreas 1 (4.2)
Abbreviations: CM: cutaneous melanoma.
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Table 2: Additional primary tumors` (APT) characteristics
Both sexes Female Male
Overall
After 
primary 
melanoma
Before 
primary 
melanoma
After primary 
melanoma
Before 
primary 
melanoma
N 93 18 14 28 33
APT type (%) Bladder 7 (7.5) 0 (0.0) 1 (7.1) 2 (7.1) 4 (12.1)
Brain & Central 
Nerves 1 (1.1) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0)
Breast 14 (15.1) 8 (44.4) 5 (35.7) 0 (0.0) 1 (3.0)
Cervix Uteri 1 (1.1) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0)
Colon, Rectum 3 (3.2) 1 (5.6) 1 (7.1) 1 (3.6) 0 (0.0)
Eye 1 (1.1) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0)
Kidney 3 (3.2) 1 (5.6) 0 (0.0) 1 (3.6) 1 (3.0)
Larynx 1 (1.1) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0)
Leukaemia 5 (5.4) 0 (0.0) 4 (28.6) 1 (3.6) 0 (0.0)
Lung, Bronchus, 
Trachea 6 (6.5) 2 (11.1) 1 (7.1) 2 (7.1) 1 (3.0)
Merkel 1 (1.1) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0)
Multiple Myeloma 3 (3.2) 0 (0.0) 0 (0.0) 2 (7.1) 1 (3.0)
Nerve sheath 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.0)
Non Hodgkin 
Lymphoma 5 (5.4) 1 (5.6) 0 (0.0) 1 (3.6) 3 (9.1)
Oesophagus 2 (2.2) 0 (0.0) 0 (0.0) 2 (7.1) 0 (0.0)
Oral Cavity & 
Pharynx 3 (3.2) 0 (0.0) 0 (0.0) 1 (3.6) 2 (6.1)
Pancreas 4 (4.3) 0 (0.0) 1 (7.1) 2 (7.1) 1 (3.0)
Pleura 1 (1.1) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0)
Prostate 23 (24.7) 0 (0.0) 0 (0.0) 6 (21.4) 17 (51.5)
Stomach 1 (1.1) 0 (0.0) 0 (0.0) 1 (3.6) 0 (0.0)
Testis 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.0)
Thyroid 6 (6.5) 4 (22.2) 0 (0.0) 2 (7.1) 0 (0.0)
Stage AJCC/
Rai (%) I 20 (21.5) 5 (27.8) 2 (14.3) 7 (25.0) 6 (18.2)
IA 5 (5.4) 2 (11.1) 2 (14.3) 0 (0.0) 1 (3.0)
IB 4 (4.3) 2 (11.1) 0 (0.0) 2 (7.1) 0 (0.0)
II 2 (2.2) 0 (0.0) 0 (0.0) 2 (7.1) 0 (0.0)
IIA 8 (8.6) 2 (11.1) 1 (7.1) 1 (3.6) 4 (12.1)
IIB 8 (8.6) 1 (5.6) 0 (0.0) 1 (3.6) 6 (18.2)
III 6 (6.5) 0 (0.0) 1 (7.1) 2 (7.1) 3 (9.1)
IIIA 3 (3.2) 0 (0.0) 1 (7.1) 1 (3.6) 1 (3.0)
IIIB 2 (2.2) 1 (5.6) 1 (7.1) 0 (0.0) 0 (0.0)
in situ 2 (2.2) 0 (0.0) 1 (7.1) 0 (0.0) 1 (3.0)
IV 13 (14.0) 3 (16.7) 1 (7.1) 5 (17.9) 4 (12.1)
IVA 2 (2.2) 0 (0.0) 0 (0.0) 1 (3.6) 1 (3.0)
Unknown 18 (19.4) 2 (11.1) 4 (28.6) 6 (21.4) 6 (18.2)
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stage IV, whereas on APT diagnosed after 39.1% 
were stage I and 19.6% stage IV (Figure 3). DCR was 
achieved in 91.5% on APT before CM and 80.5% after 
CM. 
For APT diagnosed after CM, we additionally 
analyzed the patterns of diagnosis, concluding that 28 
out of 50 APT were diagnosed at melanoma follow-up, 
including PET/CT and CT imaging, as well as clinical 
examination.  
Standardized incidence ratio (SIR) analysis
Although we had a small patient cohort, we 
calculated the expected number of APT after first 
melanoma diagnosis assuming that cancer risk in the 
cohort was similar to that observed in the German Swiss 
population (Figure 4). We found a few cancers with 
elevated incidence; breast cancers in females [SIR 2.46 
(1.06–4.86)], larynx in males [SIR 76.92 (1.01–427.9)], 
multiple myeloma in males [SIR 11.2 (1.36–40.6)], 
oesophagus in males [SIR 10.8 (1.31–39.1)] and thyroid 
cancers in both females [SIR 38.1 (10.38–97.54)] and 
males [SIR 48.8 (5.91–176.2). Overall, we found the 
SIR for our melanoma cohort to be 2.71 (1.96–3.63). 
Interestingly, prostate cancer in males showed a lower 
incidence after CM diagnosis [SIR 0.69 (0.25–1.51)].
Cutaneous melanoma and papillary thyroid 
cancer
Based on our findings that all thyroid cancer cases 
(6.5%) occurred after the first melanoma diagnosis and 
due their common papillary pathological type (PTC), 
although our small patient cohort, we aimed to assess 
the rate of BRAF V600E mutation in this patient cohort. 
We therefore performed a real-time quantitative PCR 
procedure (Idylla) of all available tumor tissues. Six 
patients with both CM and PTC were tested, of which 4 
were found to be positive for BRAF V600E mutation in 
melanoma, 6 for BRAF V600E in PTC and 4 in both.
METHODS
Patient selection and data collection
The cancer registry of the Comprehensive Cancer 
Center Zurich (CCCZ) is a melanoma reference database 
Treatment 
type (%) None 6 (6.5) 1 (5.6) 0 (0.0) 4 (14.3) 1 (3.0)
Operation 41 (44.1) 7 (38.9) 3 (21.4) 12 (42.9) 19 (57.6)
Operation and 
Radiotherapy 11 (11.8) 2 (11.1) 3 (21.4) 3 (10.7) 3 (9.1)
Operation and 
Radiotherapy and 
Systemic therapy
4 (4.3) 3 (16.7) 0 (0.0) 1 (3.6) 0 (0.0)
Operation and 
Systemic therapy 11 (11.8) 3 (16.7) 4 (28.6) 3 (10.7) 1 (3.0)
Radiotherapy 7 (7.5) 2 (11.1) 0 (0.0) 3 (10.7) 2 (6.1)
Radiotherapy and 
Systemic therapy 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.0)
Radiotherapy and 
Systemic therapy 
and Bone marrow 
transplantation
1 (1.1) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0)
Systemic therapy 10 (10.8) 0 (0.0) 2 (14.3) 2 (7.1) 6 (18.2)
Systemic therapy 
and Stem cell 
transplantation
1 (1.1) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0)
Course (%) CR 40 (43.0) 5 (27.8) 6 (42.9) 10 (35.7) 19 (57.6)
PD 12 (12.9) 3 (16.7) 2 (14.3) 6 (21.4) 1 (3.0)
PR 1 (1.1) 1 (5.6) 0 (0.0) 0 (0.0) 0 (0.0)
SD 39 (41.9) 9 (50.0) 6 (42.9) 12 (42.9) 12 (36.4)
Unknown 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.0)
Abbreviations: CR: complete response, PR: partial response, PD: progressive disease, SD: stable disease.
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Figure 2: Comparison of additional primary tumors (APT) diagnosed before and after melanoma according to sex. 
Figure 3: Time and staging distribution of additional primary tumors (APT) according to cutaneous melanoma (CM) 
diagnosis.
Oncotarget3380www.oncotarget.com
with centralized data and quality management, for skin 
cancer. CCCZ was queried for cutaneous melanoma (CM) 
patients with additional primary tumors (APT) between the 
years of 2008 and 2018, with a closing date of June 2018 
and a minimum follow up time of 6 months. Patients with 
non-melanoma skin cancers (NMSC) besides Merkel Cell 
Carcinoma (MCC), melanoma recurrence, subsequent 
second or third melanomas and benign tumors were 
excluded. Since APT in patients with metastatic disease are 
difficult to distinguish from melanoma metastases, we only 
included APT with a histologic confirmation. The tumors 
were classified according to the American Joint Committee 
on Cancer (AJCC) 7th edition. Geographic, histopathologic 
and treatment data after diagnosis of metastatic disease were 
retrospectively collected for all patients. Response evaluation 
to the systemic treatment was according to the radiologic 
RECIST 1.1 criteria. Patients` records were also searched 
for risk factors, including family history, smoke, age, 
gender and race. In order for the reported variables not to 
contribute in more than one category, for patients with a first 
and second degree relative with cancer, only the first degree 
relative was included. In order to describe the distribution of 
APT with respect to melanoma diagnosis, we labelled the 
patients into two groups; APT before and after CM. Multiple 
primary tumors (MPT) were defined as two or more separate 
neoplasms of different primary, other than melanoma. 
Follow-up time was calculated from the day of resection of 
the CM to the date of last follow-up, including last visit or 
date of death, or June 2018, whichever occurred first.
For APT occurring after CM, the standardized 
incidence ratios (SIRs) were calculated by dividing the 
observed numbers of cancer by the expected ones. The 
observed numbers of cancers and person-years at risk 
were calculated by gender, 5-year age group and the 
time since the diagnosis of CM. The expected numbers 
of cancer were obtained by multiplying the stratum-
specific numbers of person-years by the corresponding 
cancer incidence rates in German Swiss population in 
Switzerland extracted from the Nationales Institut für 
Krebsepidemiologie und -registrierung (NICER) database. 
Exact 95% confidence intervals (CIs) were defined 
when the numbers of observed cases followed a Poisson 
distribution. All analyses were conducted using statistical 
language R version 3.5. 
Written informed consent for retrospective analysis 
of melanoma patients in our registry was previously 
approved by local ethics committee (KEK-ZH 2014-
0193).  
Figure 4: Risk of additional primary tumors (APT) diagnosed after cutaneous melanoma (CM) in the study population 
compared to the expected cancer incidence rates in the German Swiss population. Abbreviations: SIR: Standardized 
Incidence Ratios with 95% Confidence Interval.
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DISCUSSION AND CONCLUSIONS
On our retrospective analysis, there is an overall 
incidence of 4.5% of an APT before and after CM 
diagnosis, among of which 16.25% attributed to MPT. 
Based on our analysis, we show that patients who were 
previously diagnosed with cutaneous melanoma (CM) 
have approximately a 2.7 fold increased risk of an APT 
compared to the general Swiss German population. 
These results are consistent with previous international 
findings reporting a significantly elevated risk for specific 
subsequent primary cancers other than melanoma in 
melanoma survivors [11], although the relatively greater 
overall risk of 28% described in the cited study. Albeit, 
a direct comparison to these data could be misleading, 
taking into consideration the differences in the population 
size, follow-up duration as well as inclusion criteria. 
Since patients with CM have an increased risk of second 
primary CM, subsequent melanomas were excluded 
from our analysis [11, 18–20]. In our patient cohort, 
female breast cancer, male larynx cancer, male multiple 
myeloma, male oesophagus cancer and thyroid cancer 
in both sexes had statistically increased incidence after 
the first melanoma diagnosis, compared to the normal 
population. The reasons for this increased risk seem to 
be multifactorial and could be contributed to increased 
medical surveillance and follow-up after CM diagnosis, 
as well as other independent, non-modifiable risk factors, 
such as the presence of an inherited genetic predisposition 
and advanced age [21, 22], and behavioral, modifiable risk 
factors, such as UV-exposure [23] and immunosuppression 
[24–26], especially for hematologic tumors. A mutual 
association between CM and female breast cancer has 
been reported in both genetic and population-based 
retrospective studies [27], suggesting a higher prevalence 
of both cancers for mutations of high‐risk genes, such 
as BRCA2 and CM [28] and CDKN2A and breast cancer 
[29, 30]. Unorthodoxly, the incidence of prostate cancer 
in our population seems to decrease after CM diagnosis, 
although this result should be cautiously interpreted, due 
to the relatively low number of this event in our patient 
cohort. The latter may be of particular interest, since 
several studies have connected CM and prostate cancer 
with common risk factors responsible for the pathogenesis 
of both cancer types, such as the UV exposure, with 
subsequently increased risk of prostate cancer diagnosis 
after melanoma diagnosis [12, 16, 31–34]. On the 
other hand, the role of androgens and oestrogens in 
the melanoma development have been controversially 
discussed [35–38]; altogether, the assumption of an 
additional biological or hormonal relationship between 
CM, prostate cancer and breast cancer remains unclear.
Interestingly, the probability of a new thyroid 
cancer diagnosis seems to increase after CM diagnosis in 
both sexes, which is in accordance of previous reported 
results [11]. Besides, the controversial relationship 
between CM and thyroid cancer has been confirmed from 
previous retrospective reviews, suggesting that patients 
with papillary thyroid cancer (PTC) are at significantly 
increased risk of CM and vice versa [39]. The precise 
etiology for this correlation is unclear; however, the 
thyroid cancer cases observed in our patient cohort had 
a common papillary histological subtype and a high 
rate of BRAFV600E mutational background, which 
was observed in both CM and PTC, thus unravelling a 
possible common genetic component of these cancers. 
This is of great importance, considering that several 
types of cancer are a result of mutations in critical genes 
[40]. Still, although every individual tumor is genetically 
distinct, the pathways affected in different tumors 
may overlap [6]. Approximately 50% of the CM cases 
harbor an activating mutation in the BRAF oncogene 
[41], whereas BRAF V600E mutations have been 
also described in approximately 44% of patients with 
papillary thyroid cancer (PTC) [42]. These results may 
indicate a common genetic pathway in the pathogenesis 
of these cancers. 
Our dataset showed that in patients with APT or 
MPT, metastatic melanoma still remains the most common 
cause of death. Yet, a large proportion of the APT are 
usually diagnosed on early stages with high DCR rates. 
There was also a significant difference among the median 
time of the diagnosis for APT before and after CM ((55.37 
months (0.30–443.17) versus 15.91 months (0–241.16)), 
which can be attributed to the patterns of care after CM 
diagnosis with regular screening during follow-up. Indeed, 
28 out of 50 APT diagnosed after CM were detected at 
melanoma follow-up, including PET/CT and CT imaging 
or clinical examination. The Swiss guidelines recommend 
an increased vigilance of follow-up in the first 10 years, 
with surveillance every 3 to 6 months the first 5 years 
and every 12 months for the next 5 years for the stage 
I-II melanoma [43]. Patients with a previous diagnosis of 
CM are more likely to have more regular and attentive 
health controls, which may increase the possibility of 
detecting APT and thus in an early stage. Still, there 
was a slight difference between stage IV APT diagnosed 
before (12.7%) and after (19.6%) CM, although a possible 
explanation for this finding is unclear. 
The main strength of our study is that the CCCZ 
registry provides a high accuracy in tumors registering 
with long and minimum loss of follow-up. Such patients 
are usually excluded from clinical trial protocols, thus 
only few prospective data are available. Our study 
emphasizes the complexity of patients with unrelated 
APT and the importance of increased follow-up for 
the prompt detection of such survival issues. Further 
research is required to unravel the burden and causative 
relationship of APT and primary tumors, as well as their 
socioeconomic impact on the survival population.
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